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Abstract
Conventional disease-modifying antirheumatic drugs such as
methotrexate are the mainstay of treatment for rheumatoid arthritis.
More recently, biologic agents such as etanercept, infliximab and
adalimumab, which act by inhibiting tumour necrosis factor (TNF),
have become available. TNF inhibitors have proved to be very
effective in patients not responding to conventional disease-
modifying antirheumatic drugs. However, about 20% to 40% of
patients treated with a TNF inhibitor fail to achieve a 20% improve-
ment in American College of Rheumatology criteria, and more lose
response over time (secondary failure or acquired therapeutic
resistance) or experience adverse events following treatment with
a TNF inhibitor. In this group of patients, therapeutic options were
limited until recently and an established treatment approach was to
switch from one TNF inhibitor to another. In recent years, thera-
peutic options in these patients have increased with the introduc-
tion of biologic agents with novel mechanisms of action, such as
rituximab and abatacept. This review outlines the current evidence
in support of the available treatment strategies in patients with an
inadequate response or intolerance to an initial TNF inhibitor.
Introduction
Rheumatoid arthritis (RA) is a chronic, progressive, debilita-
ting autoimmune disease that occurs in approximately 1% of
adults [1]. Although the disease may develop at any age, RA
occurs most commonly in people aged 40 to 70 years.
Approximately 2.5 times more women than men are affected
[1]. The disease is characterized by chronic inflammation of
the synovium, which over time results in damage to the joints,
leading to pain and disability. RA is associated with increased
mortality, particularly in older women [2,3], and it may reduce
life expectancy by 3 to 18 years [4]. Recent studies have
demonstrated that a substantial proportion of patients con-
tinue to show radiographic progression, even though clinically
they are in a state of low disease activity, suggesting that
achieving remission should be the ultimate goal [5,6].
Disease-modifying antirheumatic drugs (DMARDs) are the
mainstay of treatment for RA. Methotrexate is the most
commonly used agent in this class, and it is effective on
standard clinical measures of disease activity [7], cost-
effective and comparatively well tolerated. The development
of biologic agents represented a major advance in the
treatment of RA. The targets of biologic agents are inter-
actions between the immune effector cells (T lymphocytes,
B lymphocytes and macrophages), which are responsible for
inflammation and structural damage in affected joints, and the
signalling molecules involved in their activation. The first
approved biologic agents for the treatment of RA were
inhibitors of tumour necrosis factor (TNF). There are now
three agents available in this treatment class: etanercept,
infliximab and adalimumab. These agents are very effective at
improving the signs and symptoms, and at slowing or
preventing structural damage in patients with RA [8-14].
Newer TNF inhibitors are also in clinical development for the
treatment of RA and include golimumab [15] and certolizumab
pegol [16]. Both of these agents are effective at improving
signs and symptoms of disease, and prevention of structural
damage has been reported for certolizumab pegol [17,18].
However, anti-TNF agents are not effective in all patients.
About 30% of patients treated with a TNF inhibitor failed to
achieve an improvement of 20% in American College of
Rheumatology criteria (ACR20; primary failure or inefficacy)
[11,13,14], and more patients lose efficacy during therapy
(secondary failure or acquired therapeutic resistance) [19] or
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experience adverse events following treatment with a TNF
inhibitor.
Until recently, therapeutic options were limited for patients
not responding satisfactorily to TNF inhibitors, and who
typically have failed many conventional DMARDs and
combinations of DMARDs. Switching from one TNF inhibitor
to another has become an established treatment approach
for patients who failed or were intolerant of treatment with an
initial TNF inhibitor. This is largely because of physician
experience and familiarity with the efficacy and safety profile
of these products that has developed over the past several
years, and the strong evidence that TNF inhibitors are potent
in terms of slowing disease progression. Despite a similar
mode of action within the TNF inhibitor class, the rationale
behind switching these agents resides in variations in
bioavailability, differences in the stability of the TNF-inhibitor
complex or the potential occurrence of drug-neutralizing
antibodies [20]. Although formally none of the available TNF
inhibitors is currently approved for this indication, a recent
survey of US-based rheumatologists showed that over 94%
of respondents reported switching patients from one TNF
inhibitor to another [21]. However, this survey was conducted
at a time when biologics with a different mode of action were
not yet available.
Recently, biologic agents with novel mechanisms of action
have been approved for use in patients with RA, therefore
increasing the number of therapeutic options for patients with
inadequate response or intolerance to a first TNF inhibitor.
Rituximab, a monoclonal antibody directed against CD20+ B
cells, induces transient depletion of B cells and was recently
approved for the treatment of adult patients with severe active
RA who have exhibited an inadequate response to or were
intolerant of one or more TNF inhibitors in combination with
methotrexate [22]. Abatacept, a selective inhibitor of T-cell co-
stimulation, has been approved for the treatment of patients
who have exhibited an inadequate response to or were
intolerant of one or more DMARDs or TNF inhibitors in the
USA, or one or more TNF inhibitors only in Europe. Tocilizu-
mab, a chimeric monoclonal antibody blocking interleukin-6-
mediated signal transduction, was recently studied in patients
not responding to TNF inhibitors [23], and the European
Commission has recently approved its use in this indication.
Optimal treatment strategies have yet to be defined for
patients who have exhibited an inadequate response to or
were intolerant of an initial TNF inhibitor, because there have
been no randomized, prospective, head-to-head trials com-
paring the strategy of cycling between TNF inhibitors versus
using an agent with a different mechanism of action.
The aim of this review is to appraise the current evidence in
support of the available treatment strategies in patients with
an inadequate response or intolerance to an initial TNF
inhibitor.
Efficacy
Signs and symptoms
Data supporting cycling between TNF inhibitors are limited in
terms of both quantity and quality. Well controlled switching
trials are limited; the vast majority of current data comes from
open-label, retrospective or prospective observational studies.
Several observational studies have demonstrated an improve-
ment in disease activity in patients who have not responded
to a TNF inhibitor when switched to another TNF inhibitor.
However, the results of these studies may be biased by a
phenomenon known as ‘regression to the mean’ in that,
because patients tend to be treated with a second agent at
the height of their disease activity, there is a greater than
50-50 likelihood that disease activity will start improving after
the intervention purely by chance [24].
Results from several large studies also indicate that efficacy
may decline following cycling to a second TNF inhibitor
[25-30] (Figures 1 and 2). A recent Swedish survey [31]
identified a reduction in response when patients were
switched to their second TNF inhibitor compared with TNF
inhibitor-naïve patients, and a more marked reduction when
patients were switched to a third TNF inhibitor. An ACR20
response was achieved by 51% of first-time switchers
(n = 337) and only by 35% of second-time switchers
(n = 36). The corresponding ACR50 rates were 27% and
18%, respectively. The European League Against Rheu-
matism (EULAR) good or moderate rates were 71% and
58%, and EULAR good rates were 25% and 9%, respec-
tively. The 28-joint Disease Activity Score (DAS28) remission
rates were 16% and 6%, respectively.
The Open-label, Pilot Protocol of patients with rheumatoid
arthritis who Switch to Infliximab after an incomplete
response to Etanercept (OPPOSITE) trial [32] was a small,
randomized study, involving 28 patients, which suggested a
more favourable outcome in patients who switched to
infliximab. However, the majority of patients did not achieve
an ACR50 response. Efficacy results with subsequent TNF
inhibitor treatment appear to differ according to the reason
for switching [25,33]. Of 6,739 patients with RA whose
primary treatment with a TNF inhibitor (adalimumab, etaner-
cept or infliximab) was recorded in a large UK national bio-
logics register, 856 were switched to a second TNF inhibitor
because of inefficacy (503 patients) or adverse events (353
patients) [33]. Patients who had discontinued the first
inhibitor because of inefficacy were more likely to fail
treatment with a second inhibitor for the same reason (hazard
ratio = 2.7, 95% confidence interval [CI] = 2.1 to 3.4) rather
than toxicity (hazard ratio = 1.1, 95% CI = 0.9 to 1.5).
Similarly, rates of drug discontinuation for adverse events
were higher in patients who had previously discontinued
because of intolerance (hazard ratio = 2.3, 95% CI = 1.9 to
2.9) than in those who had previously discontinued because
of inefficacy (hazard ratio = 1.2, 95% CI = 0.8 to 1.6).Those patients failing TNF inhibitor therapy because of lack of
efficacy can be subdivided into those who never achieved an
adequate response (primary failure or inefficacy) and those
who lost response over time (secondary failure or acquired
therapeutic resistance). In general, a second TNF inhibitor
appears to be more effective in patients with a history of
secondary failure rather than primary failure, but some
heterogeneity has been seen in small studies. For instance, in
a large cohort study, RA patients were permitted to switch to
adalimumab after prior treatment with etanercept and/or
infliximab (Research in Active rheumatoid arthritis [ReAct])
[25]; responses to adalimumab appeared to be lower in
patients with primary failure than in patients with secondary
failure or intolerance (Figure 3). A preliminary report from a
Dutch registry included 128 patients who were switched
because of primary (n = 35) or secondary (n = 41) failure or
intolerance (n = 50) [34]. After the switch, all groups (inclu-
ding primary nonresponders) exhibited significant improve-
ment in DAS28 compared with baseline: -1.77 for primary
nonresponders, -1.18 for secondary nonresponders and
-1.54 for patients who were switched because of adverse
events (P = 0.189). Furthermore, in 43 patients switched to
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Figure 1
ACR20 response in patients with and without prior TNF inhibitor treatment. *P = 0.028, **P < 0.0015. Data from Kristensen et al. [28]. ACR20,
20% improvement in American College of Rheumatology criteria; TNF, tumour necrosis factor.
Figure 2
EULAR response following treatment with one or two TNF inhibitors. Data from Navarro et al. [29]. EULAR, European League Against Rheumatism;
TNF, tumour necrosis factor.another TNF inhibitor after adalimumab failure, successful
treatment was more likely if adalimumab had been stopped
because of secondary failure or intolerance [35]. The
proportions of patients with EULAR good response in each
group were 4.5% in the 22 patients with primary failure,
27.3% in patients with secondary failure and 30% in patients
who were intolerant of adalimumab. In contrast, some other
studies have indicated that response to a second TNF
inhibitor may be greater in the cohort of patients with primary
rather than secondary failure [36]. In a study in which 95
patients were switched from infliximab/methotrexate therapy
to etanercept (34 because of primary failure, 38 because of
secondary failure and 23 because of intolerance), achieve-
ment of ACR20, ACR50 and ACR70 responses was
greatest in the patients with primary infliximab failure.
Two large studies [37,38] indicated that the ‘drug survival’
time of a second TNF inhibitor is reduced in patients who had
received a prior TNF inhibitor agent. In a survey of 4,760
patients (68% with RA, 11% with ankylosing spondylitis,
10% with psoriatic arthritis and 11% with other chronic
inflammatory conditions) receiving TNF inhibitors [37], the
1-year and 2-year drug survival rates were 83% and 75%,
respectively, and were even lower in patients receiving a
second TNF inhibitor (n = 441 patients; 68% and 60% at 1
and 2 years, respectively; Figure 4). A similar trend was
observed for the third TNF inhibitor, but because the numbers
were too small (n = 47 patients) to permit meaningful
analysis, these data are not shown. A survey of TNF inhibitor-
naïve patients and those who had received a TNF inhibitor
previously was undertaken, and the duration of treatment for
50% and 75% of patients who remained on therapy was
compared [38]. The 50% drug survival time was reduced
from 26.8 months in the TNF inhibitor-naïve patients to 17.6
months in the patients who had received a TNF inhibitor
previously (P = 0.04). The corresponding values for 75%
drug survival were 6.9 and 5.3 months, respectively. Thus,
mean drug survival times were significantly reduced in
patients who had previously received one or more TNF
inhibitors.
Treatment with golimumab, a new TNF inhibitor that is under
clinical development, produced a significantly greater ACR20
response after 24 weeks when compared with placebo in
patients who had previously been treated with at least one
other TNF inhibitor and then discontinued because of lack of
efficacy (38.9% with golimumab 50 mg and 100 mg com-
bined versus 17.7% with placebo; P < 0.001) [15]. However,
the relative difference in response rates compared with
placebo in this patient population was relatively small
compared with most other earlier randomized controlled trials
of TNF inhibitors in similar populations of patients naïve to
TNF inhibitors or other biologics [11-14,39].
Overall, these findings suggest that the decline in efficacy
after a switch to a second TNF inhibitor may in part be due to
a class effect and also to a channelling bias favouring
patients with more severe disease. Thus, the rationale for
introducing agents with a different mode of action may be to
overcome issues related to class, particularly in cases of
primary failure or recurrence of class-associated adverse
events.
Rituximab, administered as two 1,000 mg infusions 14 days
apart, was shown to be effective in patients with an in-
adequate response to TNF inhibitors in a well designed,
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Figure 3
Switching TNF inhibitors: ACR response 12 weeks after switching to adalimumab. Data from Bombardieri et al. [25]. ACR, American College of
Rheumatology; TNF, tumour necrosis factor.randomized, placebo-controlled study (Randomised Evalua-
tion oF Long-term Efficacy of rituXimab in rheumatoid arthritis
[REFLEX]) [40]. In patients with active RA and an inadequate
response to TNF inhibitors, repeated courses of rituximab
yielded sustained or improved efficacy compared with original
baselines (Figure 5). In addition, achievement of EULAR good
response at week 24 was maintained or improved with
repeated courses of rituximab [41]. The efficacy of rituximab
has also been shown to be superior when it is used in
patients who have exhibited an inadequate response to a
single TNF inhibitor when compared with patients with
failures to two or more TNF inhibitors (Figure 6) [42].
Observational studies have generally confirmed the findings
from clinical trials. An analysis from a large practice-based
regional registry confirmed that rituximab therapy significantly
improved disease activity (DAS28; P < 0.0005) at 3, 6, 9 and
12 months in 114 patients with RA and an inadequate
response to at least one previous TNF inhibitor. At 6 months
and in a total of 59 patients, a moderate to good EULAR
response was seen in 62% of patients, of whom 23% had a
good response, and remission occurred in 18% [43]. Impor-
tantly, repeat treatment with rituximab produced sustained
efficacy for at least 6 months [44].
Superior efficacy of abatacept (10 mg/kg intravenous infusion
on days 1, 15 and 29, and then every 28 days thereafter)
combined with at least one DMARD relative to placebo has
been demonstrated in patients exhibiting an inadequate
response to TNF inhibitor therapy in the Abatacept Trial in
Treatment of Anti-TNF INadequate responders (ATTAIN)
study [39]. At 6 months, the ACR20 response rate was
50.4% in the abatacept group versus 19.5% in the placebo
group (P < 0.001). The ACR50 and ACR70 response rates
were also significantly higher in the abatacept group than in
the placebo group (ACR50 response: 20.3% versus 3.8%,
P < 0.001; ACR70 response: 10.2% versus 1.5%,
P = 0.003; Figure 7). Analysis of the extended, open-label
period of ATTAIN revealed that sustained improvements in
ACR responses were achieved after 2 years of treatment with
abatacept [45].
Patient-reported disability
Various groups, including EULAR, ACR and the Outcome
Measures in Rheumatology Clinical Trials group, recognize
that patient-reported outcome measures are important in
developing an understanding of patients’ experience of their
disease. One such measure, the Health Assessment Question-
naire (HAQ) disability index, captures self-perceived dis-
ability. Scores range from 0 to 3, with higher scores reflecting
increased disability. Improvements in this measure of
disability have been used in a number of studies to determine
responses to various treatment strategies.
The effect of switching between TNF inhibitors was analyzed
in patients with an inadequate response to a first TNF
inhibitor and in whom HAQ was measured at the time of
nonresponse and 12 months later [46]. Patients were
classified into three groups based on treatment during the
subsequent 12 months: those receiving no further TNF
inhibitor therapy (‘stoppers’, n = 148), those who switched to
a second TNF inhibitor (‘switchers’, n = 331) and those who
continued on their first TNF inhibitor therapy for at least a
further 9 months (‘stayers’, n = 389). The proportion of patients
who achieved a minimum clinically important difference
(defined as an improvement in HAQ of ≤0.22 units) was
higher for switchers (36%) than for stayers (31%) or
stoppers (22%; P < 0.01 versus switchers). Although these
data suggest that switching to a second TNF inhibitor is more
beneficial than discontinuing treatment and receiving no
biologic therapy during the subsequent 12 months, the
majority of patients who switched did not experience a
clinically significant improvement regarding functionality. Of
note, patients with more advanced disease and established
structural damage will be less likely to be able to regain full
functional capacity [47].
The effect on HAQ has also been determined in patients with
inadequate response to TNF inhibitors and treated with other
biologic agents. In the REFLEX study [48], more patients
treated with rituximab plus methotrexate achieved a minimum
clinically important difference after 6 months compared with
patients treated with placebo plus methotrexate (63.8%
versus 32.5%; P < 0.0001). In addition, in the ATTAIN study
more patients in the abatacept group than in the placebo
group (47.3% versus 23.3%; P < 0.001) had a clinically
meaningful improvement in HAQ (in this instance defined by
an improvement in HAQ of ≤0.3 units from baseline) [45].
Radiographic data
The efficacy of all currently available TNF inhibitors in terms of
inhibiting radiographic progression is well established in
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Figure 4
Survival curve for TNF inhibitors in BIOBADASER during the first 2 years
of use. Reproduced from Gomez-Reino et al. [37], with permission from
BioMed Central Ltd. BIOBADASER, Spanish Society of Rheumatology
Database on Biologic Products; TNF, tumour necrosis factor.patients with inadequate response to DMARDs and/or in
methotrexate-naïve patients. However, no formal studies have
demonstrated the efficacy of a second TNF inhibitor in
inhibiting radiographic progression in patients who res-
ponded inadequately to prior TNF inhibitor treatment.
However, given the capacity of TNF inhibitors to inhibit
radiographic progression, even in patients not exhibiting a
clinical response, it is unlikely that this would be substantially
different in patients switched to a second TNF inhibitor.
Rituximab is thus far the only agent that has formally demon-
strated significant slowing of structural joint damage in RA
patients with an inadequate response to or who are intolerant
of TNF inhibitors [49] (Figure 8). Results from the REFLEX
study in 517 patients with RA showed that rituximab plus
methotrexate treatment produced a significant reduction in
joint damage progression compared with placebo plus metho-
trexate. Significant reductions were shown from baseline to
56 weeks for rituximab plus methotrexate compared with
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Figure 5
ACR responses at week 24 in patients treated with multiple courses of rituximab. Data from Keystone et al. [44]. ACR, American College of
Rheumatology. 
Figure 6
ACR response rate with rituximab: impact of number of previous TNF inhibitors. The ACR response rate is superior in patients with an inadequate
response to one TNF inhibitor in comparison with patients who have received treatment with two or more previous TNF inhibitors. Data from
Kremer et al. [42]. ACR, American College of Rheumatology; TNF, tumour necrosis factor.placebo plus methotrexate in the following measures:
Genant-modified Sharp score (1.00 versus 2.31; P = 0.005),
the erosion score (0.59 versus 1.32; P = 0.011) and the joint
space narrowing score (0.41 versus 0.99; P < 0.001). This
difference is remarkable, given that the majority of patients in
the placebo group (81%) received at least one course of
rituximab, because from weeks 16 to 24 patients who had
failed to respond to treatment (<20% improvement in swollen
joint counts) could receive rescue therapy. These findings
have now been extended to 2 years [50]. Furthermore,
rituximab has been shown to inhibit radiographic progression
independent of clinical response in this patient population
[51]. As with TNF inhibitors [52], these findings suggest that
disease activity and radiographic progression can be
disconnected and are independent outcomes.
There are no specific radiographic data for abatacept in the
population of patients who respond inadequately to TNF
inhibitors. However, inhibition of radiographic progression
has been shown in inadequate responders to DMARDs in the
Abatacept in Inadequate responders to Methotrexate (AIM)
study [53]. Although golimumab and tocilizumab have been
studied in this patient population, no radiographic outcomes
have yet been presented.
Head-to-head studies
No large, double-blind, randomized, head-to-head studies
have been conducted in a population of patients exhibiting
inadequate response to a TNF inhibitor. A recently reported
observational study [54] indicated that, in a population of
patients with inadequate response to one or more TNF
inhibitors, rituximab may be more effective at controlling
disease activity than switching to an alternative TNF inhibitor
(Figure 9). A total of 116 patients with RA met the inclusion
criteria: 50 patients received rituximab (two 1,000 mg infu-
sions) and 66 received a second or third TNF inhibitor (49%,
27% and 24% were treated with adalimumab, etanercept
and infliximab, respectively). The results of this observational
study of patients enrolled in the Swiss registry found that, at
6 months, the decrease in DAS28 was greater in patients
treated with rituximab (-1.61, 95% CI = -1.97 to -1.25) than
in those treated with an alternative TNF inhibitor (-0.98, 95%
CI = -1.33 to -0.62). Of note, higher numbers of prior TNF
inhibitors were reported for rituximab-treated patients than for
those treated with an alternative TNF inhibitor (median two
versus one; P = 0.001), whereas both groups (rituximab and
alternative TNF inhibitor) were similar with regard to other
parameters at baseline.
These findings were confirmed in a recent, extended analysis
of more than 300 patients from the same cohort [55]. This
analysis further demonstrated that the relative benefit of
rituximab varied with the reason for switching from a prior
TNF inhibitor. When the motive for switching was lack of
effect with a previous TNF inhibitor, then the evolution of
DAS28 was significantly better for rituximab than for the
alternative TNF inhibitor. However, when the motive for
switching was another cause (such as an adverse event),
then the evolution of DAS28 was similar for rituximab and the
alternative TNF inhibitor. These findings were not significantly
modified by DMARD co-therapy, by the type of TNF inhibitor
or by the number of previous TNF inhibitors used.
This strategy is also supported by data from another smaller
observational study conducted in the UK in patients with RA
exhibiting an inadequate response to a TNF inhibitor [56].
After 3 months, the change in DAS28 was more favourable in
the group who received rituximab (-3.03; n = 15 patients)
than in the group who received an alternative TNF inhibitor
(-1.5; n = 24 patients).
No head-to-head studies in a TNF inadequate responder
population utilizing abatacept or tocilizumab have yet been
conducted.
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Figure 7
ACR response rates with abatacept at 6 months in the ATTAIN study. *P = 0.003, **P < 0.001. Reproduced with permission from Genovese et al.
N Engl J Med 2005, 353:1114-1123 [39]. Copyright © 2005 Massachusetts Medical Society. All rights reserved. ACR, American College of
Rheumatology; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders.Safety and tolerability
Tumour necrosis factor inhibitors
TNF inhibitors have been indicated for the treatment of RA for
more than 10 years and, as a result, they have a well
established safety profile.
There have been rare reports of opportunistic infections,
including tuberculosis (TB), which makes appropriate TB
screening mandatory before starting TNF therapy. In addition,
there have been rare reports of worsening pre-existing heart
failure and the occurrence of demyelinating diseases in
patients who have received TNF inhibitors [57,58]. Data from
the National Databank of Rheumatic Diseases suggested a
modest increase in lymphoma [59] and an increased risk for
skin cancer in patients treated with TNF inhibitors [60].
Evidence for an increased risk for serious infections and a
dose-dependent increase in malignancies was identified in a
systematic review and meta-analysis of nine placebo-
controlled trials of infliximab and adalimumab in patients with
RA [61]. The meta-analysis involved 3,493 patients who had
received TNF inhibitor treatment and 1,512 patients who
received placebo. The pooled odds ratio for malignancies
was 3.3 (95% CI = 1.2 to 9.1) and for serious infection was
2.0 (95% CI = 1.3 to 3.1), with a notably increased rate of
basal cell carcinoma [61]. However, in a recent consensus
statement it was suggested that treatment with TNF inhibitors
does not appear to increase the risk for malignancy in
patients with RA, although it is recommended that vigilance
Arthritis Research & Therapy    Vol 11 Suppl 1 Rubbert-Roth and Finckh
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Figure 8
Change at week 56 in radiographic end-points in TNF inadequate-response patients treated with rituximab. *P = 0.011, ** P = 0.005, ***P < 0.001.
Reproduced  from Keystone et al. Arthritis Rheum 2008, 59:785-793 [48], with permission from BMJ Publishing Group Ltd. TNF, tumour necrosis
factor.
Figure 9
Change in DAS28: rituximab versus switching to an alternative TNF inhibitor. DAS28, 28-joint Disease Activity Score; TNF, tumour necrosis factor.
Reproduced from Finckh et al. Arthritis Rheum 2007, 56:1417-1423 [54]. Reprinted with permission of John Wiley & Sons, Inc.for the occurrence of lymphomas and other malignancies
(including recurrence of solid tumours) remains in patients
managed with TNF inhibitors [62]. Of note, hepatosplenic
T-cell lymphomas were recently described in young patients
with Crohn’s disease [63], whereas in the Wegener’s
Granulomatosis Etanercept Trial (WGET) [64] an increased
occurrence of solid malignancies was observed when
etanercept was used in combination with cyclophosphamide
in patients with Wegener’s granulomatosis.
Because there may be a class effect, patients who fail
treatment with a TNF inhibitor because of a tolerability or
safety issue may be at increased risk for a similar safety
problem on an alternative TNF inhibitor. The risk for develop-
ing an adverse event with a second TNF inhibitor increased
twofold in patients switched because of an adverse event [33].
A study of hospitalization rates due to infection after TNF
inhibitor therapy in 2,956 patients [65] indicated that,
although the relative risk was greatest during the first year of
treatment (1.74) and decreased to 1.04 in year 3 with
continued therapy, switching to a second TNF inhibitor was
associated with a second increase in relative risk (2.10; 95%
CI = 1.36 to 3.27). Absolute rates of serious infections for
the first TNF inhibitor were 4.5 serious infections per 100
person-years as compared with 7.0 per 100 person-years for
the second TNF inhibitor. In the subset of 2,692 patients who
had been hospitalized (not necessarily because of RA but
who had it) before TNF inhibitor treatment, the incidence of
infection during the period on the first TNF inhibitor was 5.4
per 100 person-years (95% CI = 4.7 to 6.0; n = 261
infections), and that during the period on the second TNF
inhibitor was 10.0 per 100 person-years (95% CI = 7.1 to
16;  n = 26 infections). These results are consistent with
those from the ReAct study [25], a large cohort study that
investigated the effects of switching from etanercept and/or
infliximab to adalimumab. Serious infections occurred more
frequently during treatment with adalimumab in patients who
had received prior TNF inhibitor treatment (10.0 per 100
patient-years) compared with TNF inhibitor-naïve patients
(4.9 per 100 patient-years) [25].
Rituximab and abatacept
Whereas rituximab has a well established safety profile in
patients with B-cell lymphoma, data with regard to the
repeated use of rituximab for chronic diseases such as RA
are limited. The most frequent adverse events are infusion
reactions, which are usually mild to moderate in intensity. The
rate of serious infections was 5.2 per 100 patient-years in the
rituximab group and 3.7 per 100 patient-years in the placebo
group in the REFLEX study [40], which is consistent with that
seen for patients treated de novo with a TNF inhibitor in
randomized controlled trials [9,14] and in observational
studies [66,67]. Analysis of data from patients receiving up to
seven treatment courses of rituximab, representing 2,438
patient-years of exposure, suggested no increase in the rate
of serious infections with repeat courses [68]. The incidence
of adverse events decreased from 88% (931/1053) in
rituximab-treated patients after course 1 to 81%, 72% and
65% after courses 2, 3 and 4, respectively. Serious adverse
events followed a similar pattern, with the incidence of acute
infusion reactions (first infusion, each course) also reducing
with repeat courses [68].
Safety data from the 6-month ATTAIN study [39] showed that
infections were no more frequent in the abatacept group than
in the placebo group (37.6% versus 32.3%; P = 0.30).
Furthermore, the incidence of serious infections was 2.3% in
both groups, with no unusual or opportunistic infections
noted [39]. For the 6-month (double-blind) study and 18-
month (open-label) long-term extension of ATTAIN,
respectively, the following adverse event rates were detected
(per 100 patient-years) [45]: serious adverse events 34.5
and 29.4; malignancies 2.3 and 2.1, and serious infections
4.6 and 3.7.
Reductions in immunoglobulin levels have been observed in
some patients after repeat courses of rituximab, but in a
pooled analysis of three randomized trials [69] mean values
of both IgG and IgM remained well above the lower limit of
normal (LLN). The percentage of patients with serum IgG or
IgM levels below the LLN increased with the number of treat-
ment courses, but the rate of serious infection for patients
with low IgG/IgM levels was comparable to the rate in the
overall population [69]. However, these numbers are low and
warrant further observation. No opportunistic infections or
cases of TB have been reported.
After 2,438 patient-years of exposure to rituximab, a total of
36 malignancies occurred in 32 patients (3%) [68]. No
lymphoproliferative malignancies and no increased risk for
malignancy with additional courses of treatment with rituxi-
mab were observed. Eleven cases of lung cancer have been
reported in the total abatacept safety database, as compared
with the 3.5 to 12.3 expected based on RA DMARD cohorts,
and with the 3.7 to 5.0 expected based on general population
data [70]. More patient exposure and long-term safety
monitoring are warranted to establish the safety profile of
abatacept. The risk for activation of latent TB or for develop-
ing new TB when using abatacept is unknown [62]. However,
before initiating abatacept, patients should be screened for
latent TB infection with a tuberculin skin test [71]. Neverthe-
less, abatacept appears to have an acceptable safety profile
so far.
A key tolerability concern is the safety of RA therapies,
including TNF inhibitors and DMARDs, in patients with
peripheral B-cell depletion after treatment with rituximab.
Preliminary findings have indicated that the use of RA
therapies (including TNF inhibitors) in patients who had
received treatment with rituximab at a time when B-cell levels
had yet to be normalized, did not result in development of
Available online http://arthritis-research.com/supplements/11/S1
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adverse events [72]. Nevertheless, further investigation in
larger numbers of patients over time is warranted.
Conclusions
Despite the therapeutic advance that TNF inhibitors have
brought to RA treatment, more than 50% of patients fail to
achieve at least an ACR50 response, and more lose
response over time (secondary failure or acquired therapeutic
resistance) or experience adverse events after treatment with
TNF inhibitors. Observational studies have shown that some
patients who have had an inadequate response to an initial
TNF inhibitor do show an improvement in disease activity
when switched to another TNF inhibitor. However, the type of
inadequate response may be particularly important when
considering the likelihood of response to a subsequent agent.
The few observational studies that are available to address
the issue of switching to another TNF inhibitor, in patients
who previously failed one TNF blocker, clearly demonstrate
that the majority of patients do not achieve an ACR50
response.
Rituximab and abatacept - new therapeutic agents with
completely different modes of action - are now available for
patients with inadequate response to a first TNF inhibitor.
Evidence for the efficacy of switching to a second anti-TNF
agent after failing to respond to an initial one most often relies
on open, uncontrolled and nonrandomized studies, whereas
biologics with a different mode of action have been evaluated
in large randomized placebo-controlled trials. Randomized
controlled head-to-head trials in this population would
therefore be warranted to define the best treatment strategy
in these patients. Cohort studies recently suggested that
rituximab may be more effective than switching to an
alternative TNF inhibitor in patients with an inadequate
response to at least one TNF inhibitor [55,56]. These findings
suggest that biologic agents with a different mode of action
should be considered early as an alternative therapy after a
first inadequate response to a TNF inhibitor. In the absence of
randomized, prospective, head-to-head trials comparing
available therapeutic options for patients exhibiting inade-
quate response or intolerance to a TNF inhibitor, the optimal
treatment strategy is yet to be defined.
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